Publications by authors named "Tine C J Hendrickx"
Introduction: Intravenous vedolizumab is a widely used monoclonal antibody for outpatients with inflammatory bowel disease. Drug preparation is performed on the day of administration, but is time consuming, causing unnecessary in-hospital patient delay and inefficient logistics for preparation and distribution. Storage of vedolizumab ready-to-administer infusions and distribution via pneumatic air tubes could streamline logistics in the outpatient setting.
View Article and Find Full Text PDFArticle Synopsis
- A multicenter randomized controlled trial evaluated the efficacy and safety of the C5 inhibitor zilucoplan in hospitalized COVID-19 patients with systemic inflammation and hypoxemia.
- Out of 81 participants, those receiving zilucoplan showed greater improvement in oxygen levels compared to the control group, with a mortality rate of 9% versus 21% at day 28.
- Although the results were not statistically significant, findings suggest potential benefits of C5 inhibition for respiratory function and clinical outcomes, warranting further investigation in larger studies.